Fig. 3: CD4/CD8 ratio values predict response-free and overall survival in patients undergoing ICI therapy before and during treatment. | British Journal of Cancer

Fig. 3: CD4/CD8 ratio values predict response-free and overall survival in patients undergoing ICI therapy before and during treatment.

From: Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies

Fig. 3

Progression-free and overall survival is significantly higher in patients with CD4/CD8 ratio values above the median of 1.7 (a, b) and even more above the ideal cut-off of 1.25 (c, d), than in those with values below these cut-offs. During therapy with ICI, at an early (e) and late time point (f), there is a significant difference in PFS between patients with values below or above respective ideal cut-offs (for early: 1.25, for late: 1.55). Rather than static values, dynamics of CD4/CD8 ratio during therapy (increasing/decreasing) are significant predictors of OS. Patients with decreasing CD4/CD8 ratio live significantly longer than patients with increasing values, when comparing early (g) values to the baseline. For PFS, only a non-significant trend can be depicted towards more durable response in patients with decreasing ratio (h).

Back to article page